HPV Status Linked to Survival in Oropharynx Cancer

Share this content:
HPV Status Linked to Survival in Oropharynx Cancer
HPV Status Linked to Survival in Oropharynx Cancer

(HealthDay News) -- For patients with oropharynx cancer (OPC), human papillomavirus (HPV) positivity is associated with improved survival after disease progression, according to a study published online in the Journal of Clinical Oncology.

Carole Fakhry, MD, from Johns Hopkins Medical Institutions in Baltimore, and colleagues examined the risk of death after progression for patients with HPV-positive OPC relative to HPV-negative OPC. Data were collected for patients with stage III to IV OPC, enrolled onto Radiation Therapy Oncology Groups (RTOG) trial 0129 or RTOG 0522. The cohort comprised 181 patients with OPC, including 105 with p16-positive and 76 with p16-negative tumors.

RELATED: Head and Neck Cancer Resource Center

The researchers found that patients with p16-positive and p16-negative tumors had similar patterns of failure and median time to progression. Patients with p16-positive OPC had significantly improved survival rates after a median follow-up of 4 years, compared with p16-negatve patients (2-year overall survival, 54.6% vs. 27.6%; median, 2.6 vs. 0.8 years; P < 0.001).

After adjustment for tumor stage and cigarette pack-years at enrollment, the risk of death after disease progression was reduced with p16-positive tumor status (hazard ratio, 0.48) and receipt of salvage surgery (hazard ratio, 0.48) and was increased with distant versus locoregional progression (hazard ratio, 1.99).

"Tumor HPV status is a strong and independent predictor of overall survival after disease progression and should be a stratification factor for clinical trials for patients with recurrent or metastatic OPC," the researchers wrote.

Several authors disclosed financial ties to the pharmaceutical industry, including Bristol-Myers Squibb, which partially funded the study.

Reference

  1. Fakhry C, Zhang Q, Nguyen-Tan PF et al. Human Papillomavirus and Overall Survival After Progression of Oropharyngeal Squamous Cell Carcinoma. J Clin Oncol. 2014;doi:10.1200/JCO.2014.55.1937.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs